Based on the promising phase I data, VSV-IFNβ-NIS is currently being tested in an expanded cohort of patients with T-cell lymphoma, and in a Phase I/II and II studies in patients with advanced solid tumors (NCT03647163 and NCT06508463) [74–76]. This evidence concerns the gene IFNB1 and T-cell non-Hodgkin lymphoma.